Replies to post #81105 on Biotech Values

[DewDiligence]

IDIX:

Was their reticence to express a view on whether Novartis would want to proceed [with IDX184] normal caution…?

IDIX never speaks on behalf of NVS as a matter of policy.

…or is it that the results are a little short of spectacular (as the aftermarket seems to have voted)?

I don’t think the AH session is a no-confidence vote on the IDX184 monotherapy data; rather, I see it as a retreat from the turbocharged price action of the past few days, which was predicated on nothing but speculation.